Clara Truesdell, MD
Nephrology · Suwanee, GANPI 1508854811
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Amgen accounts for 62.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2023 at $9,312 and has fallen 88.2% since, to $1,101 in 2025. Among nephrology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 278 payments — averaging $57.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- Calliditas Therapeutics US Inc.$2K
- Bayer$455
- AstraZeneca$443
- OPKO Pharmaceuticals, LLC$429
- Vifor Pharma, Inc.$410
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,90012%
- Speaking & faculty fees$6,65042%
- Travel & lodging$1,3649%
- Food & beverage$5,54535%
- Education$4543%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 107 | $9,979 |
| Calliditas Therapeutics US Inc. | 17 | $2,365 |
| Bayer | 12 | $455 |
| AstraZeneca | 14 | $443 |
| OPKO Pharmaceuticals, LLC | 35 | $429 |
| Vifor Pharma, Inc. | 17 | $410 |
| Daiichi Sankyo Inc. | 9 | $354 |
| Fresenius USA Marketing, Inc. | 13 | $235 |
| Otsuka America Pharmaceutical, Inc. | 10 | $232 |
| Akebia Therapeutics Inc | 10 | $201 |
| Mallinckrodt Hospital Products Inc. | 8 | $190 |
| Travere Therapeutics, Inc. | 5 | $111 |
| Novo Nordisk | 1 | $101 |
| Novartis | 4 | $84 |
| Ardelyx, Inc. | 3 | $71 |
| Mallinckrodt Enterprises LLC | 2 | $53 |
| Boehringer Ingelheim | 2 | $49 |
| GSK | 2 | $33 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Aurinia Pharma U.S., Inc. | 2 | $25 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Nxstage Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$8,479
- TARPEYO$2,027
- INJECTAFER$243
- Kerendia$243
- Ozempic$101
How this compares
$15,913 in reported general payments places this provider in the 90th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 21 | $599,538 |
| FarxigaDapagliflozin Propanediol | 98 | $81,998 |
| VelphoroSucroferric Oxyhydroxide | 22 | $67,998 |
| OzempicSemaglutide | 11 | $12,918 |
| EliquisApixaban | 12 | $12,168 |
| JardianceEmpagliflozin | 16 | $10,178 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 15 | $9,405 |
| Sevelamer Carbonate | 38 | $5,448 |
| Torsemide | 162 | $2,311 |
| Clonidine | 18 | $1,817 |
| Nifedipine ErNifedipine | 52 | $1,286 |
| Allopurinol | 151 | $1,077 |
| Losartan Potassium | 120 | $1,074 |
| Olmesartan Medoxomil | 22 | $1,026 |
| Hydralazine Hcl | 65 | $770 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $9,979 | $599,53821 claims |
| AstraZenecaFarxiga | $443 | $81,99898 claims |
| Fresenius USA Marketing, Inc.Velphoro | $235 | $67,99822 claims |
| Novo NordiskOzempic | $101 | $12,91811 claims |
| Boehringer IngelheimJardiance | $49 | $10,17816 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $25 | $9,40515 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $27 | $27011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 388 nephrology providers in Georgia.
Other nephrology in Suwanee
- Malorie HolmesSuwanee$8K
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
- Rajendran AlappanColumbus$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.